Atrasentan Spermatogenesis and Testicular Function
A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function
Sponsor: AbbVie
This PHASE2 trial investigates Diabetes and Nephropathy and is currently completed. AbbVie leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Aug 2018 — Jun 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Bala-Cynwyd, United States, Berlin, Germany, Córdoba, Spain, Evergreen Park, United States, Laguna Hills, United States, Metairie, United States, Milan, Italy, New Orleans, United States, Norfolk, United States and 3 more location s